<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31771129</article-id>
<article-id pub-id-type="pmc">6928713</article-id>
<article-id pub-id-type="doi">10.3390/ijms20235875</article-id>
<article-id pub-id-type="publisher-id">ijms-20-05875</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Argenziano</surname>
<given-names>Maura</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-05875">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tortora</surname>
<given-names>Chiara</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-20-05875">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bellini</surname>
<given-names>Giulia</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-05875">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Di Paola</surname>
<given-names>Alessandra</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-05875">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Punzo</surname>
<given-names>Francesca</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-20-05875">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rossi</surname>
<given-names>Francesca</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-20-05875">2</xref>
<xref ref-type="corresp" rid="c1-ijms-20-05875">*</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-20-05875"><label>1</label>Department of Experimental Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy; <email>maura.argenziano@unicampania.it</email> (M.A.); <email>giulia.bellini@uniroma3.it</email> (G.B.); <email>alessandra.dipaola@unicampania.it</email> (A.D.P.); <email>francesca.punzo19@gmail.com</email> (F.P.)</aff>
<aff id="af2-ijms-20-05875"><label>2</label>Department of Women, Child, and General and Specialized Surgery, University of Campania Luigi Vanvitelli, 80138 Naples, Italy; <email>chiara.tortora@unicampania.it</email></aff>
<author-notes>
<corresp id="c1-ijms-20-05875"><label>*</label>Correspondence: <email>francesca.rossi@unicampania.it</email>; Tel.: +39-081-566-5342</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>12</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<issue>23</issue>
<elocation-id>5875</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>10</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>11</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Endocannabinoid system consists of cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors, their endogenous ligands, and the enzymes responsible for their synthesis and degradation. CB2, to a great extent, and CB1, to a lesser extent, are involved in regulating the immune response. They also regulate the inflammatory processes by inhibiting pro-inflammatory mediator release and immune cell proliferation. This review provides an overview on the role of the endocannabinoid system with a major focus on cannabinoid receptors in the pathogenesis and onset of inflammatory and autoimmune pediatric diseases, such as immune thrombocytopenia, juvenile idiopathic arthritis, inflammatory bowel disease, celiac disease, obesity, neuroinflammatory diseases, and type 1 diabetes mellitus. These disorders have a high social impact and represent a burden for the healthcare system, hence the importance of individuating more innovative and effective treatments. The endocannabinoid system could address this need, representing a possible new diagnostic marker and therapeutic target.</p>
</abstract>
<kwd-group>
<kwd>CB1 receptor</kwd>
<kwd>CB2 receptor</kwd>
<kwd>endocannabinoid system</kwd>
<kwd>inflammation</kwd>
<kwd>immune regulation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-20-05875" sec-type="intro">
<title>1. Introduction</title>
<p>The endocannabinoid (EC) system is a neuromodulator system composed of endogenous cannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), their selective receptors cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2), and all the enzymes involved in their synthesis and degradation (N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD), Monoacylglycerol lipase (MAGL), Diacylglycerol lipase (DAGL), Fatty acid amide hydrolase (FAAH)) [<xref ref-type="bibr" rid="B1-ijms-20-05875">1</xref>]. The CB1 receptor is principally expressed in the central nervous system, in particular, on brain presynaptic neurons [<xref ref-type="bibr" rid="B2-ijms-20-05875">2</xref>] and spinal cord and dorsal root ganglia [<xref ref-type="bibr" rid="B3-ijms-20-05875">3</xref>], while the CB2 receptor is mostly localized on immune peripheral cells, such as B lymphocytes, macrophages, mast cells, natural killer cells, and on the lymphatic organs, spleen, tonsils, and thymus [<xref ref-type="bibr" rid="B4-ijms-20-05875">4</xref>]. The EC system is involved in many biological functions: regulation of appetite, pain management, and also organism development since the earliest stage of gestation [<xref ref-type="bibr" rid="B5-ijms-20-05875">5</xref>]. Its capability to modulate inflammation and the immune response is surely noteworthy, considering the great clinical relevance that the regulation of these processes could have in several pathologies.</p>
<p>This review aims to give an overview on the role of cannabinoid receptors and other EC elements in pediatric inflammatory and immune diseases, such as immune thrombocytopenia, juvenile idiopathic arthritis, inflammatory bowel disease, celiac disease, obesity, neuroinflammatory diseases, and type 1 diabetes mellitus. All these pathologies share an important characteristic—they are an important burden for the healthcare system and strongly compromise the life quality of patients and their families. For this reason it is very important to identify innovative and effective therapeutic targets, and so far the EC system seems to address this need well.</p>
</sec>
<sec id="sec2-ijms-20-05875">
<title>2. The EC System in Inflammation and the Immune Response</title>
<p>The EC system has an important role in maintaining immune system homeostasis as well as in modulating inflammatory processes (<xref ref-type="fig" rid="ijms-20-05875-f001">Figure 1</xref>). Both CB1 and CB2 receptors play this crucial role, but their different localization could explain the different involvement in these biological processes. CB1 receptor exerts its function principally in the nervous system, where it influences the neurotransmitter release at axonic terminals and acts as an anti-inflammatory mediator, restoring, for example, the levels of interleukin 1 beta (IL-1β) and cyclooxygenase-2 (COX2) after inflammatory stimuli, as observed in rats by Zhang et al., 2016 [<xref ref-type="bibr" rid="B6-ijms-20-05875">6</xref>].</p>
<p>CB2 has a more consistent role in the peripheral regions, where it principally influences the immune response. A variant of CB2 encoding gene (<italic>rs35761398</italic>) has been individuated that leads to the production of a less functional receptor variant, CB2 Q63R. In the literature, it is well documented that the RR homozygote subjects are more prone to developing autoimmune disorders compared with QQ homozygote subjects [<xref ref-type="bibr" rid="B7-ijms-20-05875">7</xref>].</p>
<p>Even though the underlying biological mechanisms need to be better clarified, these functions seem to be associated with the EC system’s capability to inhibit immune cell proliferation and pro-inflammatory mediator release (cytokines, reactive oxygen species (ROS), nitric oxide, etc.) [<xref ref-type="bibr" rid="B8-ijms-20-05875">8</xref>]. Cytokines are molecules that positively or negatively mediate inflammation from its initiation to resolution and are produced by macrophages in the earliest stage of innate immune response and by T-cells during the adaptive immune response [<xref ref-type="bibr" rid="B9-ijms-20-05875">9</xref>]. Inflammation normally occurs as a defense mechanism and it is self-limiting thanks to an interplay between immune cells and several kind of cytokines [<xref ref-type="bibr" rid="B10-ijms-20-05875">10</xref>]. When immune tolerance is compromised, as is observed in autoimmune diseases, this physiological equilibrium is altered in favor of an inflammatory condition, which leads to tissue damage [<xref ref-type="bibr" rid="B11-ijms-20-05875">11</xref>]. In the literature, it is reported that the cannabinoids exert a modulatory effect on the release of several cytokines. For example, AEA attenuates the inflammation by reducing the production of the pro-inflammatory IL-6 and nitric oxide from lipopolysaccharide (LPS)-activated macrophages in vitro [<xref ref-type="bibr" rid="B12-ijms-20-05875">12</xref>]. In accordance, Klein et al. demonstrated that tetra-hydro-cannabinol (THC), a CB1 and CB2 receptor partial agonist, inhibits the production of IL-12 and interferon gamma (IFN-γ) by type 1 T helper (Th1) cells, thus showing an anti-inflammatory and immunosuppressive effect [<xref ref-type="bibr" rid="B13-ijms-20-05875">13</xref>]. Already in 1995, McCoy et al. observed that THC is able to suppress the antigen presentation and, as consequence, the activation of T helper cells [<xref ref-type="bibr" rid="B14-ijms-20-05875">14</xref>]. The metabolism of the ligand 2-AG leads to the production of arachidonic acid, which is a precursor of proinflammatory effectors, such as prostaglandins and leukotrienes [<xref ref-type="bibr" rid="B15-ijms-20-05875">15</xref>]. In 2014, Sardinha et al. used an inhibitor of MAGL in vivo, the main 2-AG degrading enzyme, observing a reduction in prostaglandins and leukotrienes production with a consequent anti-inflammatory effect [<xref ref-type="bibr" rid="B16-ijms-20-05875">16</xref>]. They also observed a reduction in adherent leucocytes number when both MAGL and FAAH were inhibited, thus supporting the anti-inflammatory role of CB2 activation.</p>
<p>In general, the drugs acting on the EC system show an inhibitory effect on the immune system, causing a reduction of B and T lymphocyte proliferation [<xref ref-type="bibr" rid="B17-ijms-20-05875">17</xref>]; inhibition of antibody production by B lymphocytes [<xref ref-type="bibr" rid="B18-ijms-20-05875">18</xref>]; reduction of chemokine and cytokine production by NK cells [<xref ref-type="bibr" rid="B19-ijms-20-05875">19</xref>,<xref ref-type="bibr" rid="B20-ijms-20-05875">20</xref>]; attenuation of migration, phagocytosis, and proinflammatory cytokine release in macrophages; and the enhancement of Mesenchymal Stromal Cells’ (MSCs) homing, immunosuppressive and anti-inflammatory activities [<xref ref-type="bibr" rid="B21-ijms-20-05875">21</xref>,<xref ref-type="bibr" rid="B22-ijms-20-05875">22</xref>,<xref ref-type="bibr" rid="B23-ijms-20-05875">23</xref>].</p>
</sec>
<sec id="sec3-ijms-20-05875">
<title>3. The EC System in Immune Thrombocytopenia</title>
<p>Immune thrombocytopenia (ITP) is an autoimmune and multifactorial disease in which autoantibodies prematurely disrupt platelets [<xref ref-type="bibr" rid="B24-ijms-20-05875">24</xref>]. It can be primary (idiopathic) or secondary to other pathologies. Taking into account the immunomodulating role of the CB2 receptor and the documented correlation between its Q63R variant and autoimmune disorders, in 2011, Rossi et al. genotyped, for the first time, 190 ITP Italian children for the <italic>CNR2</italic> rs35761398 variant [<xref ref-type="bibr" rid="B25-ijms-20-05875">25</xref>]. In the following years, Mahmoud et al. and Ezzat et al. performed similar association studies in an Egyptian ITP child population [<xref ref-type="bibr" rid="B26-ijms-20-05875">26</xref>,<xref ref-type="bibr" rid="B27-ijms-20-05875">27</xref>]. In both study populations, a strong correlation between Q63R polymorphism and the susceptibility to childhood ITP emerged. In addition to this genetic predisposition, an impairment in T-cells together with a direct cytotoxic effect of these cells [<xref ref-type="bibr" rid="B28-ijms-20-05875">28</xref>,<xref ref-type="bibr" rid="B29-ijms-20-05875">29</xref>,<xref ref-type="bibr" rid="B30-ijms-20-05875">30</xref>,<xref ref-type="bibr" rid="B31-ijms-20-05875">31</xref>] could have a key role in the still-unclear ITP pathogenesis. The literature reports the presence of activated platelet-autoreactive T cells in ITP patients and also a high Th1/Th2 ratio [<xref ref-type="bibr" rid="B32-ijms-20-05875">32</xref>] with a related alteration of cytokine release.</p>
<p>In these patients, Th1 cells produce an excess of IL-2 and INF-γ, which further exacerbates the activity of T-cells [<xref ref-type="bibr" rid="B33-ijms-20-05875">33</xref>]. Th2 cells reduce the production of the anti-inflammatory cytokine IL-10, this inhibits the cytotoxic T-cell and B-cell responses [<xref ref-type="bibr" rid="B34-ijms-20-05875">34</xref>,<xref ref-type="bibr" rid="B35-ijms-20-05875">35</xref>]. The possible involvement of this cytokine in ITP has been deeply investigated over the years. In particular, several authors found a correlation between the IL-10 (-1082) polymorphism, which is associated with an impairment in general cytokine release, and the acute form of ITP [<xref ref-type="bibr" rid="B36-ijms-20-05875">36</xref>,<xref ref-type="bibr" rid="B37-ijms-20-05875">37</xref>,<xref ref-type="bibr" rid="B38-ijms-20-05875">38</xref>,<xref ref-type="bibr" rid="B39-ijms-20-05875">39</xref>,<xref ref-type="bibr" rid="B40-ijms-20-05875">40</xref>]. It is known that both CB1 and CB2 receptors can influence the production of IL-10. Indeed, it has been reported that the selective stimulation of both receptors promotes an increase in the levels of this cytokine [<xref ref-type="bibr" rid="B41-ijms-20-05875">41</xref>,<xref ref-type="bibr" rid="B42-ijms-20-05875">42</xref>], supporting the well-described anti-inflammatory properties of the EC system. Among the alterations observed in ITP patients, there is also an impairment in the immune modulatory functions of Mesenchymal Stromal Cells (MSC). They are normally able to inhibit T- and B-cell proliferation [<xref ref-type="bibr" rid="B43-ijms-20-05875">43</xref>], whereas in ITP patients, this property is compromised together with their own proliferation [<xref ref-type="bibr" rid="B44-ijms-20-05875">44</xref>,<xref ref-type="bibr" rid="B45-ijms-20-05875">45</xref>]. It has been observed that the CB2 receptor is more frequently expressed in healthy MSCs than in MSCs obtained from ITP pediatric patients [<xref ref-type="bibr" rid="B23-ijms-20-05875">23</xref>] and that a selective stimulation of the cannabinoid receptor can restore the immunomodulatory capabilities of MSCs [<xref ref-type="bibr" rid="B46-ijms-20-05875">46</xref>]. Another well-reported aspect in the literature is the capability of AEA and 2-AG to modulate the platelets’ function and survival. Indeed, it has been observed that while AEA inhibits apoptosis in platelets [<xref ref-type="bibr" rid="B47-ijms-20-05875">47</xref>,<xref ref-type="bibr" rid="B48-ijms-20-05875">48</xref>], 2-AG works as a megakaryopoietic agent [<xref ref-type="bibr" rid="B49-ijms-20-05875">49</xref>]. In 2014, Gasperi et al. performed a study on human megakaryocytic MEG-01 cells, observing that 2-AG stimulates MEG-01 maturation and also enhances platelet production. When they inhibited MAGL, the main 2-AG degrading enzyme, these effects are even more evident [<xref ref-type="bibr" rid="B50-ijms-20-05875">50</xref>]. All of this evidence provides new insights to understand the ITP-causing mechanisms, its clinical presentation, and also to manage its outcomes.</p>
</sec>
<sec id="sec4-ijms-20-05875">
<title>4. The EC System in Juvenile Idiopathic Arthritis</title>
<p>Juvenile idiopathic arthritis (JIA) is a particular form of rheumatoid arthritis (RA), an autoimmune pathology normally affecting adults, that appears in subjects younger than 16 years-old [<xref ref-type="bibr" rid="B51-ijms-20-05875">51</xref>]. In general, RA is characterized by synovium inflammation, joint pain, and bone disruption [<xref ref-type="bibr" rid="B52-ijms-20-05875">52</xref>]. Therefore, proper treatment for this kind of pathology should avoid inflammation, contain bone destruction, and re-balance the immune response. Targeting the EC system could address these needs, also taking into account the presence in RA synovial fluid of CB receptors together with AEA, 2-AG, and the enzyme FAAH [<xref ref-type="bibr" rid="B53-ijms-20-05875">53</xref>]. In particular, several authors have reported that the inhibition of FAAH with selective drugs reduces joint inflammation in many kinds of arthritis, including RA [<xref ref-type="bibr" rid="B53-ijms-20-05875">53</xref>,<xref ref-type="bibr" rid="B54-ijms-20-05875">54</xref>]. In 2018, Falconer et al. observed that JWH-133, a CB2 selective agonist, causes a switch in macrophage phenotype from the pro-inflammatory M1 to the anti-inflammatory M2, counteracting the inflammation in collagen-induced arthritis (CIA) mice [<xref ref-type="bibr" rid="B55-ijms-20-05875">55</xref>]. Also, the knockdown of CB2 in human RA fibroblasts with siRNA inhibits the inflammatory process, causing a reduction of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNFα), IL-1β, IL-6, and IL-8 [<xref ref-type="bibr" rid="B56-ijms-20-05875">56</xref>]. The same group of cytokines is reported to be influenced by 4Q3C, another CB2 selective agonist that reduces their levels, thus showing a strong anti-inflammatory effect and its ability to reduce the osteoclast (OCs) number and activity in CIA mice [<xref ref-type="bibr" rid="B57-ijms-20-05875">57</xref>]. This is additive evidence about the well-known CB2 capabilities to counteract both inflammation and bone erosion [<xref ref-type="bibr" rid="B58-ijms-20-05875">58</xref>,<xref ref-type="bibr" rid="B59-ijms-20-05875">59</xref>,<xref ref-type="bibr" rid="B60-ijms-20-05875">60</xref>]. The latter is linked to the reduction of the receptor activator of nuclear factor kappa B ligand (RANKL) usually observed after activation of the CB2 receptor [<xref ref-type="bibr" rid="B61-ijms-20-05875">61</xref>].</p>
<p>RANKL is an important osteoclastogenic mediator, physiologically released from osteoblasts (OBs) and able to activate OCs. Any alteration of this pathway could cause a break in the deposition–resorption equilibrium in bone tissue [<xref ref-type="bibr" rid="B62-ijms-20-05875">62</xref>]. In RA, an increase in RANKL is in fact observed [<xref ref-type="bibr" rid="B63-ijms-20-05875">63</xref>], and it is known that the EC system is present in RA synovial tissue and fluid [<xref ref-type="bibr" rid="B53-ijms-20-05875">53</xref>], but not in healthy joints [<xref ref-type="bibr" rid="B64-ijms-20-05875">64</xref>]. Also, for this pathology, the anti-inflammatory function of the EC system is crucial and moreover can be associated to the modulation of immune response. Bellini et al. observed that, in a population of 171 JIA children, patients with a RR genotype for the CNR2 gene have an increased risk to develop this pathology [<xref ref-type="bibr" rid="B65-ijms-20-05875">65</xref>]. Taken together, all this evidence suggests a crucial role for CB2 receptor in pathogenesis and clinical course of both RA and, in particular, JIA.</p>
</sec>
<sec id="sec5-ijms-20-05875">
<title>5. The EC System in Inflammatory Bowel Disease and Celiac Disease</title>
<p>Inflammatory bowel diseases (IBD) are immune-mediated inflammation conditions affecting the gastro-intestinal tract, including Crohn’s disease (CRD) and ulcerative colitis (UC) [<xref ref-type="bibr" rid="B66-ijms-20-05875">66</xref>]. Several studies suggest that gut inflammation is associated with hyper-expression of cannabinoid receptors [<xref ref-type="bibr" rid="B67-ijms-20-05875">67</xref>], to increased levels of the AEA [<xref ref-type="bibr" rid="B68-ijms-20-05875">68</xref>], that suppresses T-cell proliferation and inhibits IL-2, TNF-α, and INF-γ release from activated T-lymphocytes [<xref ref-type="bibr" rid="B69-ijms-20-05875">69</xref>] and also with alteration in enzymatic pathways. In particular, in 2004, Massa et al. observed that mice deficient in FAAH, the principal AEA-degrading enzyme, are protected from colitis, and the pharmacological blockade of the CB1 receptor leads to a worsening of murine colitis [<xref ref-type="bibr" rid="B70-ijms-20-05875">70</xref>]. Also, 2-AG and the enzyme responsible for its degradation, MAGL, are involved in gut inflammation. Indeed, it has been observed that after treatment with a selective MAGL inhibitor, there is a reduction of colon inflammation in mice with induced colitis [<xref ref-type="bibr" rid="B71-ijms-20-05875">71</xref>]. Wright et al. demonstrated increased CB2 expression in the epithelium of colonic tissue in the acute phase of IBD and a reduced secretion of IL-8, suggesting an anti-inflammatory effect of the receptor [<xref ref-type="bibr" rid="B72-ijms-20-05875">72</xref>]. In accordance with this Ihenetu et al. demonstrated the same effect of CB2 activation in colonic epithelial cell lines [<xref ref-type="bibr" rid="B73-ijms-20-05875">73</xref>]. Recently, Leinwand et al. demonstrated that CB2 stimulation ameliorates inflammation in a mouse model of CRD [<xref ref-type="bibr" rid="B74-ijms-20-05875">74</xref>].</p>
<p>Moreover, it is widely known that the EC modulation ameliorates the IBD symptomatology reducing nausea, abdominal pain, and diarrhea [<xref ref-type="bibr" rid="B75-ijms-20-05875">75</xref>]. Therefore, CB2 has a double potential—to reduce the inflammation and to improve the IBD patients’ life quality. IBD is also characterized by an immune component, but in the literature, the opinions about an eventual genetic predisposition related to the Q63R variant of CB2 are discordant. While in 2014, Yonal et al. demonstrated the absence of association between this variant and IBD in a Turkish population [<xref ref-type="bibr" rid="B76-ijms-20-05875">76</xref>], a few years later, in 2018, Strisciuglio et al. demonstrated that the R63 variant is associated with a severe phenotype in both UC and CRD Italian pediatric patients [<xref ref-type="bibr" rid="B77-ijms-20-05875">77</xref>]. Race and ethnicity strongly influence the IBD incidence and phenotype [<xref ref-type="bibr" rid="B78-ijms-20-05875">78</xref>], potentially explaining the different distribution of the CB2 Q63R variant between Turkish and Italian populations.</p>
<p>Celiac disease (CD) is also described as an inflammatory and autoimmune disease of the small bowel that occurs in genetically predisposed subjects after the ingestion of gluten [<xref ref-type="bibr" rid="B79-ijms-20-05875">79</xref>]. Rossi et al. demonstrated, in a cohort of 327 CD children, a significant association between the CB2 Q63R variant and CD, confirming the role of the receptor in autoimmunity susceptibility [<xref ref-type="bibr" rid="B80-ijms-20-05875">80</xref>]. There are several in vivo and in vitro studies demonstrating an alteration of the EC system in untreated CD patients [<xref ref-type="bibr" rid="B80-ijms-20-05875">80</xref>,<xref ref-type="bibr" rid="B81-ijms-20-05875">81</xref>,<xref ref-type="bibr" rid="B82-ijms-20-05875">82</xref>]. In detail, in the active mucosa of these patients, an increase in AEA levels has been observed [<xref ref-type="bibr" rid="B68-ijms-20-05875">68</xref>], which is very likely due to the high expression of NAPE-PDL, the main enzyme responsible for AEA synthesis, observed in vivo by Battista et al., 2012 [<xref ref-type="bibr" rid="B81-ijms-20-05875">81</xref>]. In untreated celiacs, celiacs on a gluten-free diet, and controls, the same authors did not observe any variation in FAAH, which is instead the principal AEA-degrading enzyme. Moreover, it an increase in the expression of the CB2 receptor has been observed both in the duodenal mucosa and in the atrophic villous during active disease, whereas CB receptor levels are normal in treated CD patients. It is probable that the increase in CB2 levels is due to lymphocyte infiltration, in particular, to CD4+ T-cells [<xref ref-type="bibr" rid="B83-ijms-20-05875">83</xref>] that produce the pro-inflammatory component IL-17. Therefore, the selective stimulation of CB2, by means of AEA for example, could exert an immunosuppressive effect reducing IL-17 production. Interestingly, the ex vivo incubation of celiac biopsies with gliadin increases the expression of both receptors [<xref ref-type="bibr" rid="B80-ijms-20-05875">80</xref>,<xref ref-type="bibr" rid="B84-ijms-20-05875">84</xref>]. In conclusion, a deregulation of the EC system could be implicated in the pathogenesis of CD but further studies are certainly needed to clarify its therapeutic role.</p>
</sec>
<sec id="sec6-ijms-20-05875">
<title>6. The EC System in Obesity and Fatty Liver Disease</title>
<p>Obesity is one of the most diffused diseases worldwide and represents an important public health problem. In recent years, a critical increase of childhood obesity has been observed, the most common cause of which is excessive caloric intake compared with the actual caloric expenditure in genetically predisposed subjects [<xref ref-type="bibr" rid="B85-ijms-20-05875">85</xref>]. It is characterized by a low-grade inflammation in white adipose tissue, which leads to the production and secretion of inflammatory mediators responsible for attracting macrophages and other cells of the immune system [<xref ref-type="bibr" rid="B86-ijms-20-05875">86</xref>]. In particular, over the years, many authors investigated the possible connection between the pro-inflammatory mediators TNF-α and IL-6 and obesity in children. Data present in the literature are discordant. Indeed, while in several study populations, there are no differences in these cytokine levels between normal- and over-weight children [<xref ref-type="bibr" rid="B87-ijms-20-05875">87</xref>,<xref ref-type="bibr" rid="B88-ijms-20-05875">88</xref>], in 2008, Cabellero et al. reported raised levels of TNF-α in obese Hispanic children [<xref ref-type="bibr" rid="B89-ijms-20-05875">89</xref>]. It has been demonstrated that the EC system modulation is involved in regulating obesity [<xref ref-type="bibr" rid="B90-ijms-20-05875">90</xref>,<xref ref-type="bibr" rid="B91-ijms-20-05875">91</xref>], but CB1 and CB2 receptors play different roles. While CB1 activation induces increasing inflammatory processes [<xref ref-type="bibr" rid="B92-ijms-20-05875">92</xref>], CB2 activation ameliorates the inflammatory state related to obesity [<xref ref-type="bibr" rid="B93-ijms-20-05875">93</xref>]. Actually, there are different opinions about the role of CB2 in obesity. Indeed, in 2010, Pacher and Mechoulam described it as a “cannabinoid receptor with an identity crisis” [<xref ref-type="bibr" rid="B94-ijms-20-05875">94</xref>]. Some authors observed that 2-month-old CB2 –/– mice under a high-fat diet did not show weight gain, indicating that a lack of CB2 has protective effects [<xref ref-type="bibr" rid="B95-ijms-20-05875">95</xref>] and even its stimulation can correlate with an increase in inflammation [<xref ref-type="bibr" rid="B96-ijms-20-05875">96</xref>]. However, data suggesting anti-inflammatory properties of CB2 remain more representative. It is well documented, for example, that the CB2 receptor agonist JWH-133 in mice is able to inhibit auto-reactive T cells, thus preventing leukocyte migration into the inflamed tissue [<xref ref-type="bibr" rid="B97-ijms-20-05875">97</xref>].</p>
<p>The stimulation of CB2 leads also to another important protective effect in adipocytes from obese subjects: the increase of uncoupling protein 1 (UCP1) levels and consequently of heat generation and energy expenditure [<xref ref-type="bibr" rid="B98-ijms-20-05875">98</xref>]. In support of the CB2 protective role, for obesity, a strong association with CB2 Q63R variant has also been observed. Indeed, children expressing this variant show an increase in weight and high levels of pro-inflammatory cytokines (IL-6 and TNF-α). When the CB2 receptor is selectively stimulated with JWH-133, this critical condition is restored in primary cultures of adipocytes obtained from obese subjects [<xref ref-type="bibr" rid="B93-ijms-20-05875">93</xref>,<xref ref-type="bibr" rid="B98-ijms-20-05875">98</xref>,<xref ref-type="bibr" rid="B99-ijms-20-05875">99</xref>]. Another polymorphism positively associated with obesity is the FAAH polymorphism rs324420 that reduces FAAH activity, leading to higher AEA levels and consequent over-activation of CB1 receptors, which, in turn, causes adipogenesis and a high obesity risk [<xref ref-type="bibr" rid="B100-ijms-20-05875">100</xref>,<xref ref-type="bibr" rid="B101-ijms-20-05875">101</xref>]. The secretion of pro-inflammatory mediators by adipose tissue can increase the risk of developing secondary pathologies, such as type 2 diabetes, cardiovascular diseases, cancer, and non-alcoholic fatty liver disease (NAFLD) [<xref ref-type="bibr" rid="B102-ijms-20-05875">102</xref>]. It has been observed that the CB2 Q63R variant is also present in subjects with NAFLD and is associated with high-grade inflammation in the liver [<xref ref-type="bibr" rid="B103-ijms-20-05875">103</xref>]. Since CB1 and CB2 receptors are also expressed in this organ, their regulation could be important for reducing liver impairments, as demonstrated also by Coppola et al. in patients with chronic hepatitis C (HCV) [<xref ref-type="bibr" rid="B103-ijms-20-05875">103</xref>,<xref ref-type="bibr" rid="B104-ijms-20-05875">104</xref>,<xref ref-type="bibr" rid="B105-ijms-20-05875">105</xref>,<xref ref-type="bibr" rid="B106-ijms-20-05875">106</xref>,<xref ref-type="bibr" rid="B107-ijms-20-05875">107</xref>]. In collecting all of this evidence, it is possible to suggest the EC system as pathological marker and pharmacological target to manage, not only the obesity-associated inflammation, but also its secondary complications.</p>
</sec>
<sec id="sec7-ijms-20-05875">
<title>7. The EC System in Neuroinflammatory Diseases</title>
<p>Neuroinflammation is an inflammatory process that aims to defend the brain in case of damage, but it can evolve into a chronic pathological condition. It can be associated with several pathologies, such as Alzheimer’s disease, Parkinson’s disease, schizophrenia, bipolarism, and also, regarding pediatric patients, neurodevelopment disorders, such as autism spectrum disorders and epilepsy [<xref ref-type="bibr" rid="B108-ijms-20-05875">108</xref>,<xref ref-type="bibr" rid="B109-ijms-20-05875">109</xref>,<xref ref-type="bibr" rid="B110-ijms-20-05875">110</xref>]. The CB1 receptor has a widespread distribution in the brain, particularly in the pre-synaptic region on axon terminals [<xref ref-type="bibr" rid="B111-ijms-20-05875">111</xref>,<xref ref-type="bibr" rid="B112-ijms-20-05875">112</xref>,<xref ref-type="bibr" rid="B113-ijms-20-05875">113</xref>] and it seems to be responsible for the protection of neurons from death associated with neuroinflammation [<xref ref-type="bibr" rid="B114-ijms-20-05875">114</xref>]. While its stimulation with selective agonists inhibits the release of pro-inflammatory mediators (nitric oxide, TNF-α, and COX-2) [<xref ref-type="bibr" rid="B115-ijms-20-05875">115</xref>,<xref ref-type="bibr" rid="B116-ijms-20-05875">116</xref>], its ablation up-regulates the microglia activity as observed in CNR1 –/– mice, in which the hippocampus expression of the pro-inflammatory cytokine IL-6 was high [<xref ref-type="bibr" rid="B117-ijms-20-05875">117</xref>]. Microglia cells are brain-resident macrophages involved in these pathological conditions and they constitutively express the CB1 receptor (<xref ref-type="fig" rid="ijms-20-05875-f002">Figure 2</xref>). They can be activated as pro-inflammatory M1 and then release cytokines such as TNF-α, IL-6, and IL-1β, or as anti-inflammatory M2 and release inflammation-inhibiting factors such as IL-10. In the literature, the involvement of the FAAH enzyme in modulating microglia cell activation has been widely hypothesized [<xref ref-type="bibr" rid="B118-ijms-20-05875">118</xref>,<xref ref-type="bibr" rid="B119-ijms-20-05875">119</xref>]. One of the most recent studies about the role of FAAH highlighted that its knockdown in BV2 microglia cells and the related increase of AEA levels leads to an overexpression of M2 markers, revealing an important anti-inflammatory effect [<xref ref-type="bibr" rid="B120-ijms-20-05875">120</xref>]. During inflammatory processes, the microglia cells over express the CB1 receptor and release a consistent amount of cytokines and mediators that damage cells.</p>
<p>Several authors have reported that the selective stimulation of the receptor reduces microglia activity, thus exerting neuroprotection [<xref ref-type="bibr" rid="B121-ijms-20-05875">121</xref>]. For all these reasons, there is a growing interest in targeting the EC system for treatment of different neurological diseases. Epidiolex is the first cannabidiol-based drug approved by the Food and Drug Administration (FDA) for the treatment of childhood epilepsies, such as Dravet syndrome and Lennox–Gastaut syndrome [<xref ref-type="bibr" rid="B122-ijms-20-05875">122</xref>]. As indicated by Devinsky et al., 2015, 137 epileptic children patients who received this drug self-reported a reduction of seizure frequency by 54% without significant side effects (somnolence, decreased appetite, and diarrhea) [<xref ref-type="bibr" rid="B123-ijms-20-05875">123</xref>]. Even if it is less present in neuronal compartments, the CB2 receptor could also have a role in neuroinflammation. Siniscalco et al. performed a study using a population of 22 autistic children from which a CB2 up-regulation in peripheral blood mononuclear cells (PBMCs) emerged. This observation obviously generates the hypothesis of a possible involvement of the EC system in pathogenesis of autism spectrum disorders and highlights the possibility of using the CB2 receptor as a therapeutic target [<xref ref-type="bibr" rid="B124-ijms-20-05875">124</xref>], thus avoiding the psychotropic effects that often derive from CB1 stimulation.</p>
</sec>
<sec id="sec8-ijms-20-05875">
<title>8. The EC System in Type 1 Diabetes Mellitus</title>
<p>Type 1 diabetes mellitus (T1DM) is an autoimmune metabolic disorder due to the destruction of insulin-producing pancreatic β-cells by a specific auto-antibody that, over the years, strongly compromises patients’ life quality [<xref ref-type="bibr" rid="B125-ijms-20-05875">125</xref>]. Despite T1DM being defined as a chronic autoimmune disease, there is evidence about a crucial role of inflammation and oxidative stress in its pathophysiology. In 2016, Domingueti et al. observed that inflammatory biomarkers, such IL-6 and TNF-α, are increased in diabetic patients with micro- and macro-vascular complications [<xref ref-type="bibr" rid="B126-ijms-20-05875">126</xref>]. Both human and rat pancreatic β-cells express the CB2 receptor [<xref ref-type="bibr" rid="B127-ijms-20-05875">127</xref>]. Considering the CB2 capacity to reduce pro-inflammatory mediators when properly stimulated [<xref ref-type="bibr" rid="B128-ijms-20-05875">128</xref>], there is a growing interest in using it as pharmacological target to contain the effects of the disease [<xref ref-type="bibr" rid="B129-ijms-20-05875">129</xref>,<xref ref-type="bibr" rid="B130-ijms-20-05875">130</xref>].</p>
<p>In the literature, there are several preclinical studies performed on rodents with streptozotocin (STZ, a pancreatic β-cell cytotoxin) induced T1DM, in which it has been demonstrated how the stimulation of CB2 with drugs can ameliorate the symptoms of the disease, such as hyperalgesia [<xref ref-type="bibr" rid="B131-ijms-20-05875">131</xref>,<xref ref-type="bibr" rid="B132-ijms-20-05875">132</xref>]. Moreover Zoja et al. observed that in kidney biopsies from patients with diabetic nephropathy, CB2 is down-regulated, and moreover, its deletion worsens the kidney state, confirming the receptor protective action [<xref ref-type="bibr" rid="B129-ijms-20-05875">129</xref>]. Moriarty et al. observed that STZ-diabetic rats show an alteration in CB1 receptor functionality in the substantia nigra, which may be associated with diabetes and diabetic neuropathic pain [<xref ref-type="bibr" rid="B133-ijms-20-05875">133</xref>]. Surely all of this evidence needs further investigation, but new perspectives for the management of this complex degenerative disease are surely emerging.</p>
</sec>
<sec id="sec9-ijms-20-05875" sec-type="conclusions">
<title>9. Conclusions</title>
<p>Starting from the well-known EC system capabilities to modulate inflammation and the immune response, many authors have demonstrated its involvement in the pathogenesis and in the onset of several childhood pathologies (immune thrombocytopenia, juvenile idiopathic arthritis, inflammatory bowel disease, celiac disease, obesity, neuroinflammatory diseases, and type 1 diabetes mellitus) (<xref ref-type="table" rid="ijms-20-05875-t001">Table 1</xref>). They are able to influence the production of inflammatory mediators by mechanisms that are still unclear. In particular, their proper stimulation inhibits the secretion of pro-inflammatory factors and also reduces the activation and the toxic effects of the immune cells. It clearly emerges from this review that CB2 receptors could be the best pharmacological target. Indeed, because of its peripheral localization, its stimulation is associated with a lower risk of psychotropic side effects compared with the stimulation of CB1. This aspect is crucial in supporting the possibility to introduce the CB2 selective agonists in the therapeutic protocols as safe and effective additive drugs. This innovative intervention could represent a strong aid to ameliorate not only the onset of these pathologies but also the life quality of affected children.</p>
<p>Moreover, it is important to remember that the diseases explored in this review are characterized not only by their primary symptomatology but also by secondary consequences, which will certainly have an impact on the health of ‘future’ adults. Furthermore, avoiding a lifelong follow-up of these patients, at least for comorbidities, should be a great clinical success and also reduce the related costs for the healthcare system.</p>
<p>The <xref ref-type="table" rid="ijms-20-05875-t001">Table 1</xref> summarizes the main alterations of the endocannabinoid receptors (CB1 and CB2), their endogenous ligands (AEA and 2-AG), and the enzymes responsible for their synthesis and degradation (NAPE-PLD, FAAH, MAGL) in pediatric inflammatory and immune diseases.</p>
</sec>
</body>
<back>
<notes>
<title>Funding</title>
<p>This research received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-ijms-20-05875">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guzman</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cannabinoids: Potential anticancer agents</article-title>
<source/>Nat. Rev. Cancer
          <year>2003</year>
<volume>3</volume>
<fpage>745</fpage>
<lpage>755</lpage>
<pub-id pub-id-type="doi">10.1038/nrc1188</pub-id>
<pub-id pub-id-type="pmid">14570037</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-20-05875">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freund</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>Katona</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Piomelli</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Role of endogenous cannabinoids in synaptic signaling</article-title>
<source/>Physiol. Rev.
          <year>2003</year>
<volume>83</volume>
<fpage>1017</fpage>
<lpage>1066</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00004.2003</pub-id>
<pub-id pub-id-type="pmid">12843414</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-20-05875">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farquhar-Smith</surname>
<given-names>W.P.</given-names>
</name>
<name>
<surname>Egertova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bradbury</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Elphick</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Cannabinoid CB(1) receptor expression in rat spinal cord</article-title>
<source/>Mol. Cell. Neurosci.
          <year>2000</year>
<volume>15</volume>
<fpage>510</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="doi">10.1006/mcne.2000.0844</pub-id>
<pub-id pub-id-type="pmid">10860578</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-20-05875">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piomelli</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>The molecular logic of endocannabinoid signalling</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2003</year>
<volume>4</volume>
<fpage>873</fpage>
<lpage>884</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1247</pub-id>
<pub-id pub-id-type="pmid">14595399</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-20-05875">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fride</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>The endocannabinoid-CB receptor system: Importance for development and in pediatric disease</article-title>
<source/>Neuro. Endocrinol. Lett.
          <year>2004</year>
<volume>25</volume>
<fpage>24</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">15159678</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-20-05875">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Antagonism of cannabinoid receptor 1 attenuates the anti-inflammatory effects of electroacupuncture in a rodent model of migraine</article-title>
<source/>Acupunct. Med.
          <year>2016</year>
<volume>34</volume>
<fpage>463</fpage>
<lpage>470</lpage>
<pub-id pub-id-type="doi">10.1136/acupmed-2016-011113</pub-id>
<pub-id pub-id-type="pmid">27834685</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-20-05875">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sipe</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Arbour</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gerber</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Beutler</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: Possible risk for autoimmune disorders</article-title>
<source/>J. Leukoc. Biol.
          <year>2005</year>
<volume>78</volume>
<fpage>231</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="doi">10.1189/jlb.0205111</pub-id>
<pub-id pub-id-type="pmid">15845647</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-20-05875">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donvito</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nass</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Wilkerson</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Curry</surname>
<given-names>Z.A.</given-names>
</name>
<name>
<surname>Schurman</surname>
<given-names>L.D.</given-names>
</name>
<name>
<surname>Kinsey</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Lichtman</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain</article-title>
<source/>Neuropsychopharmacology
          <year>2018</year>
<volume>43</volume>
<fpage>52</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2017.204</pub-id>
<pub-id pub-id-type="pmid">28857069</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-20-05875">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyman</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Purton</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Surh</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Sprent</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Cytokines and T-cell homeostasis</article-title>
<source/>Curr. Opin. Immunol.
          <year>2007</year>
<volume>19</volume>
<fpage>320</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="doi">10.1016/j.coi.2007.04.015</pub-id>
<pub-id pub-id-type="pmid">17433869</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-20-05875">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.Z.</given-names>
</name>
</person-group>
<article-title>Drug targets in the cytokine universe for autoimmune disease</article-title>
<source/>Trends Immunol.
          <year>2013</year>
<volume>34</volume>
<fpage>120</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1016/j.it.2012.10.003</pub-id>
<pub-id pub-id-type="pmid">23116550</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-20-05875">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moudgil</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Choubey</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Cytokines in autoimmunity: Role in induction, regulation, and treatment</article-title>
<source/>J. Interferon Cytokine Res.
          <year>2011</year>
<volume>31</volume>
<fpage>695</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="doi">10.1089/jir.2011.0065</pub-id>
<pub-id pub-id-type="pmid">21942420</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-20-05875">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W.W.</given-names>
</name>
</person-group>
<article-title>Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: Involvement of eicosanoids</article-title>
<source/>J. Cell. Biochem
          <year>2001</year>
<volume>81</volume>
<fpage>715</fpage>
<lpage>723</lpage>
<pub-id pub-id-type="doi">10.1002/jcb.1103</pub-id>
<pub-id pub-id-type="pmid">11329626</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-20-05875">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Cabral</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>Cannabinoid-induced immune suppression and modulation of antigen-presenting cells</article-title>
<source/>J. Neuroimmune Pharmacol.
          <year>2006</year>
<volume>1</volume>
<fpage>50</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1007/s11481-005-9007-x</pub-id>
<pub-id pub-id-type="pmid">18040791</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-20-05875">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCoy</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Gainey</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cabral</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>delta 9-Tetrahydrocannabinol modulates antigen processing by macrophages</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>1995</year>
<volume>273</volume>
<fpage>1216</fpage>
<lpage>1223</lpage>
<pub-id pub-id-type="pmid">7791094</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-20-05875">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chouinard</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lefebvre</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bouchard</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ferland</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lalancette-Hebert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marsolais</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Laviolette</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Flamand</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>The endocannabinoid 2-arachidonoyl-glycerol activates human neutrophils: Critical role of its hydrolysis and de novo leukotriene B4 biosynthesis</article-title>
<source/>J. Immunol.
          <year>2011</year>
<volume>186</volume>
<fpage>3188</fpage>
<lpage>3196</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1002853</pub-id>
<pub-id pub-id-type="pmid">21278347</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-20-05875">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sardinha</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis</article-title>
<source/>Mediators Inflamm.
          <year>2014</year>
<volume>2014</volume>
<fpage>978678</fpage>
<pub-id pub-id-type="doi">10.1155/2014/978678</pub-id>
<pub-id pub-id-type="pmid">24803745</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-20-05875">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rockwell</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Raman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Kaminski</surname>
<given-names>N.E.</given-names>
</name>
</person-group>
<article-title>A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells</article-title>
<source/>Biochem. Pharmacol.
          <year>2008</year>
<volume>76</volume>
<fpage>353</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2008.05.005</pub-id>
<pub-id pub-id-type="pmid">18571623</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-20-05875">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carayon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Marchand</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dussossoy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Derocq</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Jbilo</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Bord</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bouaboula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Galiegue</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mondiere</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Penarier</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation</article-title>
<source/>Blood
          <year>1998</year>
<volume>92</volume>
<fpage>3605</fpage>
<lpage>3615</lpage>
<pub-id pub-id-type="doi">10.1182/blood.V92.10.3605</pub-id>
<pub-id pub-id-type="pmid">9808554</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-20-05875">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The cannabinoid system and cytokine network</article-title>
<source/>Proc. Soc. Exp. Biol Med.
          <year>2000</year>
<volume>225</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1046/j.1525-1373.2000.22501.x</pub-id>
<pub-id pub-id-type="pmid">10998193</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-20-05875">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugamura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sugiyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nozaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Matsuzawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Izumiya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaikita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Obata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takeya</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages</article-title>
<source/>Circulation
          <year>2009</year>
<volume>119</volume>
<fpage>28</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.811992</pub-id>
<pub-id pub-id-type="pmid">19103987</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-20-05875">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prasanna</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Gopalakrishnan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shankar</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Vasandan</surname>
<given-names>A.B.</given-names>
</name>
</person-group>
<article-title>Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e9016</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0009016</pub-id>
<pub-id pub-id-type="pmid">20126406</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-20-05875">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keating</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Mesenchymal stromal cells: New directions</article-title>
<source/>Cell Stem Cell
          <year>2012</year>
<volume>10</volume>
<fpage>709</fpage>
<lpage>716</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2012.05.015</pub-id>
<pub-id pub-id-type="pmid">22704511</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-20-05875">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bernardo</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Luongo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Conforti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Manzo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Guida</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cristino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Imperatore</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Petrosino</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The cannabinoid receptor type 2 as mediator of mesenchymal stromal cell immunosuppressive properties</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e80022</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0080022</pub-id>
<pub-id pub-id-type="pmid">24312195</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-20-05875">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quach</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Dragovich</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Syed</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>De Meyer</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets</article-title>
<source/>Blood
          <year>2018</year>
<volume>131</volume>
<fpage>787</fpage>
<lpage>796</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2017-05-784975</pub-id>
<pub-id pub-id-type="pmid">29203584</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-20-05875">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mancusi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Roberti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Punzo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Vetrella</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Matarese</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Nobili</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Maione</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Perrotta</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura</article-title>
<source/>Haematologica
          <year>2011</year>
<volume>96</volume>
<fpage>1883</fpage>
<lpage>1885</lpage>
<pub-id pub-id-type="doi">10.3324/haematol.2011.045732</pub-id>
<pub-id pub-id-type="pmid">21828121</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-20-05875">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ezzat</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Hammam</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>El-Malah</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Khattab</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Mangoud</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Role of Cannabinoid CB2 Receptor Gene (CNR2) Polymorphism in Children with Immune Thrombocytopenic Purpura in Beni-Suef Governorate in Egypt</article-title>
<source/>Egypt J. Immunol.
          <year>2017</year>
<volume>24</volume>
<fpage>57</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="pmid">29120578</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-20-05875">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahmoud Gouda</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mohamed Kamel</surname>
<given-names>N.R.</given-names>
</name>
</person-group>
<article-title>Cannabinoid CB2 receptor gene (CNR2) polymorphism is associated with chronic childhood immune thrombocytopenia in Egypt</article-title>
<source/>Blood Coagul. Fibrinolysis
          <year>2013</year>
<volume>24</volume>
<fpage>247</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="doi">10.1097/MBC.0b013e32835aba1d</pub-id>
<pub-id pub-id-type="pmid">23406660</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-20-05875">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Audia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mahevas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Samson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Godeau</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bonnotte</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Pathogenesis of immune thrombocytopenia</article-title>
<source/>Autoimmun Rev.
          <year>2017</year>
<volume>16</volume>
<fpage>620</fpage>
<lpage>632</lpage>
<pub-id pub-id-type="doi">10.1016/j.autrev.2017.04.012</pub-id>
<pub-id pub-id-type="pmid">28428120</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-20-05875">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The Levels of T Lymphocyte Subsets in Immune Thrombocytopenia Associated with Anti-GPIIb/IIIa- and/or Anti-GPIbalpha-Mediated Responses Are Differentially Sensitive to Dexamethasone</article-title>
<source/>Acta Haematol.
          <year>2018</year>
<volume>140</volume>
<fpage>60</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1159/000491977</pub-id>
<pub-id pub-id-type="pmid">30130794</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-20-05875">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Z.C.</given-names>
</name>
</person-group>
<article-title>Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura</article-title>
<source/>Eur J. Haematol.
          <year>2007</year>
<volume>78</volume>
<fpage>139</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-0609.2006.00780.x</pub-id>
<pub-id pub-id-type="pmid">17328716</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-20-05875">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yazdanbakhsh</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Imbalanced immune homeostasis in immune thrombocytopenia</article-title>
<source/>Semin. Hematol.
          <year>2016</year>
<volume>53</volume>
<fpage>S16</fpage>
<lpage>S19</lpage>
<pub-id pub-id-type="doi">10.1053/j.seminhematol.2016.04.006</pub-id>
<pub-id pub-id-type="pmid">27312156</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-20-05875">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Handa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kojima</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Amagai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tsumita</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kaneko</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tsukamoto</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nojima</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura</article-title>
<source/>Eur. J. Haematol.
          <year>2003</year>
<volume>71</volume>
<fpage>283</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="doi">10.1034/j.1600-0609.2003.00138.x</pub-id>
<pub-id pub-id-type="pmid">12950238</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-20-05875">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perera</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garrido</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Advances in the pathophysiology of primary immune thrombocytopenia</article-title>
<source/>Hematology
          <year>2017</year>
<volume>22</volume>
<fpage>41</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1080/10245332.2016.1219497</pub-id>
<pub-id pub-id-type="pmid">27670221</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-20-05875">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Flavell</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Contextual regulation of inflammation: A duet by transforming growth factor-beta and interleukin-10</article-title>
<source/>Immunity
          <year>2008</year>
<volume>28</volume>
<fpage>468</fpage>
<lpage>476</lpage>
<pub-id pub-id-type="doi">10.1016/j.immuni.2008.03.003</pub-id>
<pub-id pub-id-type="pmid">18400189</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-20-05875">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geginat</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Larghi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Paroni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nizzoli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Penatti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pagani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gagliani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Meroni</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Abrignani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Flavell</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer</article-title>
<source/>Cytokine Growth Factor Rev.
          <year>2016</year>
<volume>30</volume>
<fpage>87</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1016/j.cytogfr.2016.02.003</pub-id>
<pub-id pub-id-type="pmid">26980675</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-20-05875">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Relationship between the IL-10 (-1082 A/G) polymorphism and the risk of immune/idiopathic thrombocytopenic purpura: A meta-analysis</article-title>
<source/>Cytokine
          <year>2019</year>
<volume>125</volume>
<fpage>154820</fpage>
<pub-id pub-id-type="doi">10.1016/j.cyto.2019.154820</pub-id>
<pub-id pub-id-type="pmid">31493564</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-20-05875">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saitoh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kasamatsu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mitsui</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Koiso</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yokohama</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Handa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matsushima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tsukamoto</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Karasawa</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interleukin-10 gene polymorphism reflects the severity of chronic immune thrombocytopenia in Japanese patients</article-title>
<source/>Int J. Lab. Hematol.
          <year>2011</year>
<volume>33</volume>
<fpage>526</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="doi">10.1111/j.1751-553X.2011.01320.x</pub-id>
<pub-id pub-id-type="pmid">21463487</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-20-05875">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tesse</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Del Vecchio</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>De Mattia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sangerardi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Valente</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Association of interleukin-(IL)10 haplotypes and serum IL-10 levels in the progression of childhood immune thrombocytopenic purpura</article-title>
<source/>Gene
          <year>2012</year>
<volume>505</volume>
<fpage>53</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2012.05.050</pub-id>
<pub-id pub-id-type="pmid">22677268</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-20-05875">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Ghannam</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fawzy</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Azmy</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hakim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Eid</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Relation of interleukin-10 Promoter Polymorphisms to Adult Chronic Immune Thrombocytopenic Purpura in a Cohort of Egyptian Population</article-title>
<source/>Immunol. Invest.
          <year>2015</year>
<volume>44</volume>
<fpage>616</fpage>
<lpage>626</lpage>
<pub-id pub-id-type="doi">10.3109/08820139.2015.1064948</pub-id>
<pub-id pub-id-type="pmid">26436850</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-20-05875">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soliman</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Helwa</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Fath-Allah</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>El-Hawy</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Badr</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Barseem</surname>
<given-names>N.F.</given-names>
</name>
</person-group>
<article-title>IL-10 polymorphisms and T-cell subsets could affect the clinical presentation and outcome of childhood immune thrombocytopenia in Egyptian population</article-title>
<source/>APMIS
          <year>2018</year>
<volume>126</volume>
<fpage>380</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.1111/apm.12823</pub-id>
<pub-id pub-id-type="pmid">29696721</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-20-05875">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tahamtan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tavakoli-Yaraki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shadab</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rezaei</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Marashi</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Shokri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mokhatri-Azad</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Salimi</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>The Role of Cannabinoid Receptor 1 in the Immunopathology of Respiratory Syncytial Virus</article-title>
<source/>Viral Immunol.
          <year>2018</year>
<volume>31</volume>
<fpage>292</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1089/vim.2017.0098</pub-id>
<pub-id pub-id-type="pmid">29461930</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-20-05875">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Meissler</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Adler</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Eisenstein</surname>
<given-names>T.K.</given-names>
</name>
</person-group>
<article-title>A CB2-Selective Cannabinoid Suppresses T-Cell Activities and Increases Tregs and IL-10</article-title>
<source/>J. Neuroimmune Pharmacol.
          <year>2015</year>
<volume>10</volume>
<fpage>318</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="doi">10.1007/s11481-015-9611-3</pub-id>
<pub-id pub-id-type="pmid">25980325</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-20-05875">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Motan</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Tse</surname>
<given-names>H.F.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Q.L.</given-names>
</name>
<name>
<surname>Lian</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Mesenchymal stem cells and immunomodulation: Current status and future prospects</article-title>
<source/>Cell Death Dis.
          <year>2016</year>
<volume>7</volume>
<fpage>e2062</fpage>
<pub-id pub-id-type="doi">10.1038/cddis.2015.327</pub-id>
<pub-id pub-id-type="pmid">26794657</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-20-05875">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez-Simon</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Tabera</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sarasquete</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Diez-Campelo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Canchado</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sanchez-Abarca</surname>
<given-names>L.I.</given-names>
</name>
<name>
<surname>Blanco</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Alberca</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Herrero-Sanchez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Canizo</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura</article-title>
<source/>Cytotherapy
          <year>2009</year>
<volume>11</volume>
<fpage>698</fpage>
<lpage>705</lpage>
<pub-id pub-id-type="doi">10.3109/14653240903051558</pub-id>
<pub-id pub-id-type="pmid">19878056</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-20-05875">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.L.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Long Zheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.H.</given-names>
</name>
</person-group>
<article-title>Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia</article-title>
<source/>Funct. Integr. Genomics
          <year>2018</year>
<volume>18</volume>
<fpage>287</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1007/s10142-018-0591-2</pub-id>
<pub-id pub-id-type="pmid">29442265</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-20-05875">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tortora</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Palumbo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Punzo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Argenziano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Casale</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Paola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Locatelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Perrotta</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>CB2 Receptor Stimulation and Dexamethasone Restore the Anti-Inflammatory and Immune-Regulatory Properties of Mesenchymal Stromal Cells of Children with Immune Thrombocytopenia</article-title>
<source/>Int. J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<elocation-id>1049</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms20051049</pub-id>
<pub-id pub-id-type="pmid">30823385</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-20-05875">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maccarrone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Del Principe</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Finazzi-Agro</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Endocannabinoids: New physiological (co-)agonists of human platelets</article-title>
<source/>Thromb. Haemost.
          <year>2002</year>
<volume>88</volume>
<fpage>165</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="pmid">12152663</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-20-05875">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catani</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Gasperi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Finazzi Agro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Avigliano</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maccarrone</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Anandamide extends platelets survival through CB(1)-dependent Akt signaling</article-title>
<source/>Cell. Mol. Life Sci.
          <year>2010</year>
<volume>67</volume>
<fpage>601</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-009-0198-9</pub-id>
<pub-id pub-id-type="pmid">19936621</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-20-05875">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catani</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Fezza</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Baldassarri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gasperi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bertoni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pasquariello</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Finazzi-Agro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sinigaglia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Avigliano</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maccarrone</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Expression of the endocannabinoid system in the bi-potential HEL cell line: Commitment to the megakaryoblastic lineage by 2-arachidonoylglycerol</article-title>
<source/>J. Mol. Med.
          <year>2009</year>
<volume>87</volume>
<fpage>65</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1007/s00109-008-0406-3</pub-id>
<pub-id pub-id-type="pmid">18820887</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-20-05875">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gasperi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Avigliano</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Oddi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chiurchiu</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lanuti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Maccarrone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Valeria Catani</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>2-Arachidonoylglycerol enhances platelet formation from human megakaryoblasts</article-title>
<source/>Cell cycle
          <year>2014</year>
<volume>13</volume>
<fpage>3938</fpage>
<lpage>3947</lpage>
<pub-id pub-id-type="doi">10.4161/15384101.2014.982941</pub-id>
<pub-id pub-id-type="pmid">25427281</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-20-05875">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pazirandeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bonafede</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McMorrow</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis</article-title>
<source/>Clinicoecon Outcomes Res.
          <year>2019</year>
<volume>11</volume>
<fpage>361</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="doi">10.2147/CEOR.S197117</pub-id>
<pub-id pub-id-type="pmid">31213863</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-20-05875">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Takayanagi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Osteoclasts, rheumatoid arthritis, and osteoimmunology</article-title>
<source/>Curr. Opin. Rheumatol.
          <year>2006</year>
<volume>18</volume>
<fpage>419</fpage>
<lpage>426</lpage>
<pub-id pub-id-type="doi">10.1097/01.bor.0000231912.24740.a5</pub-id>
<pub-id pub-id-type="pmid">16763464</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-20-05875">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richardson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Kurian</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Latif</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Garle</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Kendall</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Scammell</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Reeve</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis</article-title>
<source/>Arthritis Res. Ther.
          <year>2008</year>
<volume>10</volume>
<fpage>R43</fpage>
<pub-id pub-id-type="doi">10.1186/ar2401</pub-id>
<pub-id pub-id-type="pmid">18416822</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-20-05875">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDougall</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Muley</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Philpott</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Krustev</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice</article-title>
<source/>Arthritis Res. Ther.
          <year>2017</year>
<volume>19</volume>
<fpage>106</fpage>
<pub-id pub-id-type="doi">10.1186/s13075-017-1313-1</pub-id>
<pub-id pub-id-type="pmid">28545594</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-20-05875">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falconer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Tiziani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>C.D.</given-names>
</name>
</person-group>
<article-title>Review: Synovial Cell Metabolism and Chronic Inflammation in Rheumatoid Arthritis</article-title>
<source/>Arthritis Rheumatol.
          <year>2018</year>
<volume>70</volume>
<fpage>984</fpage>
<lpage>999</lpage>
<pub-id pub-id-type="doi">10.1002/art.40504</pub-id>
<pub-id pub-id-type="pmid">29579371</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-20-05875">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fechtner</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Role of cannabinoid receptor 2 in mediating interleukin-1beta-induced inflammation in rheumatoid arthritis synovial fibroblasts</article-title>
<source/>Clin. Exp. Rheumatol.
          <year>2019</year>
</element-citation>
</ref>
<ref id="B57-ijms-20-05875">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A selective CB2 agonist protects against the inflammatory response and joint destruction in collagen-induced arthritis mice</article-title>
<source/>Biomed. Pharmacother.
          <year>2019</year>
<volume>116</volume>
<fpage>109025</fpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2019.109025</pub-id>
<pub-id pub-id-type="pmid">31154267</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-20-05875">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Idris</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>van ’t Hof</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Greig</surname>
<given-names>I.R.</given-names>
</name>
<name>
<surname>Ridge</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Ralston</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors</article-title>
<source/>Nat. Med.
          <year>2005</year>
<volume>11</volume>
<fpage>774</fpage>
<lpage>779</lpage>
<pub-id pub-id-type="doi">10.1038/nm1255</pub-id>
<pub-id pub-id-type="pmid">15908955</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-20-05875">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ofek</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Attar-Namdar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kram</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dvir-Ginzberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mechoulam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Frenkel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shohami</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bab</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts</article-title>
<source/>J. Bone Miner. Res.
          <year>2011</year>
<volume>26</volume>
<fpage>308</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1002/jbmr.228</pub-id>
<pub-id pub-id-type="pmid">20803555</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-20-05875">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tortora</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Punzo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Argenziano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Paola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Torella</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perrotta</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The Endocannabinoid/Endovanilloid System in Bone: From Osteoporosis to Osteosarcoma</article-title>
<source/>Int J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<elocation-id>1919</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms20081919</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-20-05875">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tortora</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bernardo</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Luongo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Conforti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Starc</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Manzo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Nobili</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Locatelli</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CB(2) and TRPV(1) receptors oppositely modulate in vitro human osteoblast activity</article-title>
<source/>Pharmacol. Res.
          <year>2015</year>
<volume>99</volume>
<fpage>194</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2015.06.010</pub-id>
<pub-id pub-id-type="pmid">26117426</pub-id>
</element-citation>
</ref>
<ref id="B62-ijms-20-05875">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tyrovola</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Spyropoulos</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Makou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perrea</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Root resorption and the OPG/RANKL/RANK system: A mini review</article-title>
<source/>J. Oral Sci.
          <year>2008</year>
<volume>50</volume>
<fpage>367</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="doi">10.2334/josnusd.50.367</pub-id>
<pub-id pub-id-type="pmid">19106463</pub-id>
</element-citation>
</ref>
<ref id="B63-ijms-20-05875">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geusens</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Landewe</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Garnero</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dunstan</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Lems</surname>
<given-names>W.F.</given-names>
</name>
<name>
<surname>Stinissen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>van der Heijde</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>van der Linden</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Boers</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction</article-title>
<source/>Arthritis Rheum.
          <year>2006</year>
<volume>54</volume>
<fpage>1772</fpage>
<lpage>1777</lpage>
<pub-id pub-id-type="doi">10.1002/art.21896</pub-id>
<pub-id pub-id-type="pmid">16736519</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-20-05875">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cannabinoid Receptor 2 Agonist Prevents Local and Systemic Inflammatory Bone Destruction in Rheumatoid Arthritis</article-title>
<source/>J. Bone Miner. Res.
          <year>2019</year>
<volume>34</volume>
<fpage>739</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="doi">10.1002/jbmr.3637</pub-id>
<pub-id pub-id-type="pmid">30508319</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-20-05875">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Olivieri</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Grandone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alessio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gicchino</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Nobili</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Perrone</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maione</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>del Giudice</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Association between cannabinoid receptor type 2 Q63R variant and oligo/polyarticular juvenile idiopathic arthritis</article-title>
<source/>Scand. J. Rheumatol.
          <year>2015</year>
<volume>44</volume>
<fpage>284</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.3109/03009742.2015.1020863</pub-id>
<pub-id pub-id-type="pmid">25974389</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-20-05875">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Peyrin-Biroulet</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Eisenhut</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>J.I.</given-names>
</name>
</person-group>
<article-title>IBD immunopathogenesis: A comprehensive review of inflammatory molecules</article-title>
<source/>Autoimmun. Rev.
          <year>2017</year>
<volume>16</volume>
<fpage>416</fpage>
<lpage>426</lpage>
<pub-id pub-id-type="doi">10.1016/j.autrev.2017.02.013</pub-id>
<pub-id pub-id-type="pmid">28212924</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-20-05875">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Marzo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Izzo</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>Endocannabinoid overactivity and intestinal inflammation</article-title>
<source/>Gut
          <year>2006</year>
<volume>55</volume>
<fpage>1373</fpage>
<lpage>1376</lpage>
<pub-id pub-id-type="doi">10.1136/gut.2005.090472</pub-id>
<pub-id pub-id-type="pmid">16966693</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-20-05875">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Argenio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Valenti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Scaglione</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cosenza</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sorrentini</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Di Marzo</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation</article-title>
<source/>FASEB J.
          <year>2006</year>
<volume>20</volume>
<fpage>568</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="doi">10.1096/fj.05-4943fje</pub-id>
<pub-id pub-id-type="pmid">16403786</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-20-05875">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cencioni</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Chiurchiu</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Catanzaro</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Borsellino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bernardi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Battistini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maccarrone</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors</article-title>
<source/>PLoS ONE
          <year>2010</year>
<volume>5</volume>
<elocation-id>e8688</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0008688</pub-id>
<pub-id pub-id-type="pmid">20098669</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-20-05875">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massa</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Marsicano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hermann</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cannich</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Monory</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cravatt</surname>
<given-names>B.F.</given-names>
</name>
<name>
<surname>Ferri</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Sibaev</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Storr</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lutz</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>The endogenous cannabinoid system protects against colonic inflammation</article-title>
<source/>J. Clin. Invest.
          <year>2004</year>
<volume>113</volume>
<fpage>1202</fpage>
<lpage>1209</lpage>
<pub-id pub-id-type="doi">10.1172/JCI200419465</pub-id>
<pub-id pub-id-type="pmid">15085199</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-20-05875">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alhouayek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Delzenne</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Cani</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Muccioli</surname>
<given-names>G.G.</given-names>
</name>
</person-group>
<article-title>Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation</article-title>
<source/>FASEB J.
          <year>2011</year>
<volume>25</volume>
<fpage>2711</fpage>
<lpage>2721</lpage>
<pub-id pub-id-type="doi">10.1096/fj.10-176602</pub-id>
<pub-id pub-id-type="pmid">21551239</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-20-05875">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rooney</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Feeney</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tate</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Welham</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Differential expression of cannabinoid receptors in the human colon: Cannabinoids promote epithelial wound healing</article-title>
<source/>Gastroenterology
          <year>2005</year>
<volume>129</volume>
<fpage>437</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="doi">10.1016/j.gastro.2005.05.026</pub-id>
<pub-id pub-id-type="pmid">16083701</pub-id>
</element-citation>
</ref>
<ref id="B73-ijms-20-05875">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ihenetu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Molleman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Whelan</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids</article-title>
<source/>Eur. J. Pharmacol.
          <year>2003</year>
<volume>458</volume>
<fpage>207</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-2999(02)02698-5</pub-id>
<pub-id pub-id-type="pmid">12498928</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-20-05875">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leinwand</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Jedlicka</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kao</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>de Zoeten</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moaddel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wehkamp</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ostaff</surname>
<given-names>M.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease</article-title>
<source/>J. Crohns Colitis
          <year>2017</year>
<volume>11</volume>
<fpage>1369</fpage>
<lpage>1380</lpage>
<pub-id pub-id-type="doi">10.1093/ecco-jcc/jjx096</pub-id>
<pub-id pub-id-type="pmid">28981653</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-20-05875">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uranga</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Vera</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Abalo</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Cannabinoid pharmacology and therapy in gut disorders</article-title>
<source/>Biochem. Pharmacol.
          <year>2018</year>
<volume>157</volume>
<fpage>134</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2018.07.048</pub-id>
<pub-id pub-id-type="pmid">30076849</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-20-05875">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yonal</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Eren</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Atug</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Over</surname>
<given-names>H.H.</given-names>
</name>
</person-group>
<article-title>No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects</article-title>
<source/>Turk. J. Gastroenterol.
          <year>2014</year>
<volume>25</volume>
<fpage>639</fpage>
<lpage>643</lpage>
<pub-id pub-id-type="doi">10.5152/tjg.2014.6568</pub-id>
<pub-id pub-id-type="pmid">25599774</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-20-05875">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strisciuglio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Miele</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cenni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tortora</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tolone</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Miraglia Del Giudice</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Cannabinoid Receptor 2 Functional Variant Contributes to the Risk for Pediatric Inflammatory Bowel Disease</article-title>
<source/>J. Clin. Gastroenterol.
          <year>2018</year>
<volume>52</volume>
<fpage>e37</fpage>
<lpage>e43</lpage>
<pub-id pub-id-type="doi">10.1097/MCG.0000000000000755</pub-id>
<pub-id pub-id-type="pmid">27875353</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-20-05875">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sellin</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Impact of race and ethnicity on inflammatory bowel disease</article-title>
<source/>Am. J. Gastroenterol.
          <year>2005</year>
<volume>100</volume>
<fpage>2254</fpage>
<lpage>2261</lpage>
<pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.00233.x</pub-id>
<pub-id pub-id-type="pmid">16181378</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-20-05875">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tye-Din</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Galipeau</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Agardh</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Celiac Disease: A Review of Current Concepts in Pathogenesis, Prevention, and Novel Therapies</article-title>
<source/>Front. Pediatr.
          <year>2018</year>
<volume>6</volume>
<fpage>350</fpage>
<pub-id pub-id-type="doi">10.3389/fped.2018.00350</pub-id>
<pub-id pub-id-type="pmid">30519552</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-20-05875">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tolone</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Luongo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mancusi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Papparella</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sturgeon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fasano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nobili</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Perrone</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: Implication for a novel molecular biomarker and future therapeutic intervention</article-title>
<source/>Pharmacol Res.
          <year>2012</year>
<volume>66</volume>
<fpage>88</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2012.03.011</pub-id>
<pub-id pub-id-type="pmid">22465144</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-20-05875">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Battista</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Di Sabatino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Tommaso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biancheri</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rapino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vidali</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Papadia</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Montana</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pasini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lanzini</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal anandamide metabolism in celiac disease</article-title>
<source/>J. Nutr. Biochem.
          <year>2012</year>
<volume>23</volume>
<fpage>1245</fpage>
<lpage>1248</lpage>
<pub-id pub-id-type="doi">10.1016/j.jnutbio.2011.06.017</pub-id>
<pub-id pub-id-type="pmid">22209002</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-20-05875">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Argenio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Petrosino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gianfrani</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Valenti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Scaglione</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Grandone</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Nigam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sorrentini</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mazzarella</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Di Marzo</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats</article-title>
<source/>J. Mol. Med.
          <year>2007</year>
<volume>85</volume>
<fpage>523</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="doi">10.1007/s00109-007-0192-3</pub-id>
<pub-id pub-id-type="pmid">17396241</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-20-05875">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maiuri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ciacci</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ricciardelli</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Vacca</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Raia</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Auricchio</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Picard</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Osman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Quaratino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Londei</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease</article-title>
<source/>Lancet
          <year>2003</year>
<volume>362</volume>
<fpage>30</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(03)13803-2</pub-id>
<pub-id pub-id-type="pmid">12853196</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-20-05875">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Battista</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Di Sabatino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Tommaso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biancheri</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rapino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Giuffrida</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Papadia</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Montana</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pasini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vanoli</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered expression of type-1 and type-2 cannabinoid receptors in celiac disease</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e62078</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0062078</pub-id>
<pub-id pub-id-type="pmid">23620805</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-20-05875">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>A.S.</given-names>
</name>
</person-group>
<article-title>Review of Childhood Obesity: From Epidemiology, Etiology, and Comorbidities to Clinical Assessment and Treatment</article-title>
<source/>Mayo Clin. Proc.
          <year>2017</year>
<volume>92</volume>
<fpage>251</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="doi">10.1016/j.mayocp.2016.09.017</pub-id>
<pub-id pub-id-type="pmid">28065514</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-20-05875">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tam</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Clement</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Baur</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Tordjman</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Obesity and low-grade inflammation: A paediatric perspective</article-title>
<source/>Obes. Rev.
          <year>2010</year>
<volume>11</volume>
<fpage>118</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1111/j.1467-789X.2009.00674.x</pub-id>
<pub-id pub-id-type="pmid">19845868</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-20-05875">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maffeis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Silvagni</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bonadonna</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Grezzani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Banzato</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tato</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Fat cell size, insulin sensitivity, and inflammation in obese children</article-title>
<source/>J. Pediatr.
          <year>2007</year>
<volume>151</volume>
<fpage>647</fpage>
<lpage>652</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpeds.2007.04.053</pub-id>
<pub-id pub-id-type="pmid">18035146</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-20-05875">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valle Jimenez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Estepa</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Camacho</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Estrada</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Luna</surname>
<given-names>F.G.</given-names>
</name>
<name>
<surname>Guitarte</surname>
<given-names>F.B.</given-names>
</name>
</person-group>
<article-title>Endothelial dysfunction is related to insulin resistance and inflammatory biomarker levels in obese prepubertal children</article-title>
<source/>Eur. J. Endocrinol.
          <year>2007</year>
<volume>156</volume>
<fpage>497</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="doi">10.1530/EJE-06-0662</pub-id>
<pub-id pub-id-type="pmid">17389466</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-20-05875">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caballero</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Bousquet-Santos</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Robles-Osorio</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Montagnani</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Soodini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Porramatikul</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hamdy</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Nobrega</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Horton</surname>
<given-names>E.S.</given-names>
</name>
</person-group>
<article-title>Overweight Latino children and adolescents have marked endothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance</article-title>
<source/>Diabetes Care
          <year>2008</year>
<volume>31</volume>
<fpage>576</fpage>
<lpage>582</lpage>
<pub-id pub-id-type="doi">10.2337/dc07-1540</pub-id>
<pub-id pub-id-type="pmid">18083792</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-20-05875">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watkins</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The endocannabinoid system: Directing eating behavior and macronutrient metabolism</article-title>
<source/>Front. Psychol.
          <year>2014</year>
<volume>5</volume>
<fpage>1506</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyg.2014.01506</pub-id>
<pub-id pub-id-type="pmid">25610411</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-20-05875">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Punzo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Umano</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Argenziano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miraglia Del Giudice</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Role of Cannabinoids in Obesity</article-title>
<source/>Int. J. Mol. Sci.
          <year>2018</year>
<volume>19</volume>
<elocation-id>2690</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms19092690</pub-id>
<pub-id pub-id-type="pmid">30201891</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-20-05875">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruiz de Azua</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mancini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Rey</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Cardinal</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tedesco</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zingaretti</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Sassmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Quarta</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schwitter</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages</article-title>
<source/>J. Clin. Invest.
          <year>2017</year>
<volume>127</volume>
<fpage>4148</fpage>
<lpage>4162</lpage>
<pub-id pub-id-type="doi">10.1172/JCI83626</pub-id>
<pub-id pub-id-type="pmid">29035280</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-20-05875">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alshaarawy</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Kurjan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Truong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>L.K.</given-names>
</name>
</person-group>
<article-title>Diet-Induced Obesity in Cannabinoid-2 Receptor Knockout Mice and Cannabinoid Receptor 1/2 Double-Knockout Mice</article-title>
<source/>Obesity (Silver Spring)
          <year>2019</year>
<volume>27</volume>
<fpage>454</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="doi">10.1002/oby.22403</pub-id>
<pub-id pub-id-type="pmid">30699233</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-20-05875">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pacher</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mechoulam</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Is lipid signaling through cannabinoid 2 receptors part of a protective system?</article-title>
<source/>Prog. Lipid Res.
          <year>2011</year>
<volume>50</volume>
<fpage>193</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1016/j.plipres.2011.01.001</pub-id>
<pub-id pub-id-type="pmid">21295074</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-20-05875">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agudo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Roca</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Molas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bura</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bosch</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Maldonado</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age</article-title>
<source/>Diabetologia
          <year>2010</year>
<volume>53</volume>
<fpage>2629</fpage>
<lpage>2640</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-010-1894-6</pub-id>
<pub-id pub-id-type="pmid">20835701</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-20-05875">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deveaux</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cadoudal</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ichigotani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Teixeira-Clerc</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Louvet</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Manin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nhieu</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Belot</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Even</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis</article-title>
<source/>PLoS ONE
          <year>2009</year>
<volume>4</volume>
<elocation-id>e5844</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0005844</pub-id>
<pub-id pub-id-type="pmid">19513120</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-20-05875">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Manivannan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cabay</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pertwee</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Coutts</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Forrester</surname>
<given-names>J.V.</given-names>
</name>
</person-group>
<article-title>Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis</article-title>
<source/>J. Leukoc. Biol.
          <year>2007</year>
<volume>82</volume>
<fpage>532</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1189/jlb.0307159</pub-id>
<pub-id pub-id-type="pmid">17537989</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-20-05875">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Luongo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Manzo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tolone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tortora</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bernardo</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Grandone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Conforti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Docimo</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cannabinoid Receptor 2 as Antiobesity Target: Inflammation, Fat Storage, and Browning Modulation</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2016</year>
<volume>101</volume>
<fpage>3469</fpage>
<lpage>3478</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2015-4381</pub-id>
<pub-id pub-id-type="pmid">27294325</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-20-05875">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishiguro</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Carpio</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Higuchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schanz</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Benno</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Arinami</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Onaivi</surname>
<given-names>E.S.</given-names>
</name>
</person-group>
<article-title>A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands</article-title>
<source/>Synapse
          <year>2010</year>
<volume>64</volume>
<fpage>92</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1002/syn.20714</pub-id>
<pub-id pub-id-type="pmid">19768813</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-20-05875">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doris</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Idris</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>O’Sullivan</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>Genetic polymorphisms of the endocannabinoid system in obesity and diabetes</article-title>
<source/>Diabetes. Obes. Metab.
          <year>2019</year>
<volume>21</volume>
<fpage>382</fpage>
<lpage>387</lpage>
<pub-id pub-id-type="doi">10.1111/dom.13504</pub-id>
<pub-id pub-id-type="pmid">30129173</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-20-05875">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Luis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Aller</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Izaola</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Conde</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gonzalez Sagrado</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Genetic variation in the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and their influence on weight loss and insulin resistance under a high monounsaturated fat hypocaloric diet</article-title>
<source/>J. Diabetes Complications
          <year>2013</year>
<volume>27</volume>
<fpage>235</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1016/j.jdiacomp.2012.11.001</pub-id>
<pub-id pub-id-type="pmid">23333123</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-20-05875">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Unamuno</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gomez-Ambrosi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Becerril</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fruhbeck</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Catalan</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Adipokine dysregulation and adipose tissue inflammation in human obesity</article-title>
<source/>Eur. J. Clin. Invest.
          <year>2018</year>
<volume>48</volume>
<fpage>e12997</fpage>
<pub-id pub-id-type="doi">10.1111/eci.12997</pub-id>
<pub-id pub-id-type="pmid">29995306</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-20-05875">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Alisi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alterio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maione</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Perrone</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Locatelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Miraglia del Giudice</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nobili</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease</article-title>
<source/>PLoS ONE
          <year>2012</year>
<volume>7</volume>
<elocation-id>e42259</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0042259</pub-id>
<pub-id pub-id-type="pmid">22927922</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-20-05875">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bazwinsky-Wutschke</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Zipprich</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dehghani</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis</article-title>
<source/>Int. J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<elocation-id>2516</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms20102516</pub-id>
<pub-id pub-id-type="pmid">31121839</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-20-05875">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van de Velde</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bekaert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Geerts</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hoorens</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Batens</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Samyah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ouwens</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Van Nieuwenhove</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lapauw</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Insulin resistance associates with hepatic lobular inflammation in subjects with obesity</article-title>
<source/>Endocr. Connect.
          <year>2019</year>
<volume>8</volume>
<fpage>1294</fpage>
<lpage>1301</lpage>
<pub-id pub-id-type="doi">10.1530/EC-19-0366</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-20-05875">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coppola</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zampino</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Macera</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marrone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pisaturo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Boemio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nobili</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pasquale</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Maione</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C</article-title>
<source/>Clin. Gastroenterol. Hepatol.
          <year>2014</year>
<volume>12</volume>
<fpage>334</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="doi">10.1016/j.cgh.2013.05.008</pub-id>
<pub-id pub-id-type="pmid">23707465</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-20-05875">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coppola</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zampino</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bellini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Stanzione</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Capoluongo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Marrone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Macera</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Adinolfi</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Giudice</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Gentile</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection</article-title>
<source/>Dig. Liver Dis.
          <year>2016</year>
<volume>48</volume>
<fpage>1364</fpage>
<lpage>1369</lpage>
<pub-id pub-id-type="doi">10.1016/j.dld.2016.07.005</pub-id>
<pub-id pub-id-type="pmid">27476469</pub-id>
</element-citation>
</ref>
<ref id="B108-ijms-20-05875">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Ting</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>The pathogenic role of the inflammasome in neurodegenerative diseases</article-title>
<source/>J. Neurochem.
          <year>2016</year>
<volume>136</volume>
<fpage>29</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13217</pub-id>
<pub-id pub-id-type="pmid">26119245</pub-id>
</element-citation>
</ref>
<ref id="B109-ijms-20-05875">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bjorklund</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Saad</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chirumbolo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kern</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Geier</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Geier</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Urbina</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Immune dysfunction and neuroinflammation in autism spectrum disorder</article-title>
<source/>Acta Neurobiol. Exp. (Wars)
          <year>2016</year>
<volume>76</volume>
<fpage>257</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="doi">10.21307/ane-2017-025</pub-id>
<pub-id pub-id-type="pmid">28094817</pub-id>
</element-citation>
</ref>
<ref id="B110-ijms-20-05875">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terrone</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Salamone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vezzani</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation</article-title>
<source/>Curr. Pharm. Des.
          <year>2017</year>
<volume>23</volume>
<fpage>5569</fpage>
<lpage>5576</lpage>
<pub-id pub-id-type="doi">10.2174/1381612823666170926113754</pub-id>
<pub-id pub-id-type="pmid">28950818</pub-id>
</element-citation>
</ref>
<ref id="B111-ijms-20-05875">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koppel</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Brust</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Fife</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bronstein</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Youssof</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gronseth</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gloss</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology</article-title>
<source/>Neurology
          <year>2014</year>
<volume>82</volume>
<fpage>1556</fpage>
<lpage>1563</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000000363</pub-id>
<pub-id pub-id-type="pmid">24778283</pub-id>
</element-citation>
</ref>
<ref id="B112-ijms-20-05875">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Cascio</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pertwee</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Whalley</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism</article-title>
<source/>Br. J. Pharmacol.
          <year>2013</year>
<volume>170</volume>
<fpage>679</fpage>
<lpage>692</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12321</pub-id>
<pub-id pub-id-type="pmid">23902406</pub-id>
</element-citation>
</ref>
<ref id="B113-ijms-20-05875">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rom</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Persidsky</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Cannabinoid receptor 2: Potential role in immunomodulation and neuroinflammation</article-title>
<source/>J. Neuroimmune Pharmacol.
          <year>2013</year>
<volume>8</volume>
<fpage>608</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="doi">10.1007/s11481-013-9445-9</pub-id>
<pub-id pub-id-type="pmid">23471521</pub-id>
</element-citation>
</ref>
<ref id="B114-ijms-20-05875">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mastinu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Premoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ferrari-Toninelli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tambaro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maccarinelli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Memo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bonini</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Cannabinoids in health and disease: Pharmacological potential in metabolic syndrome and neuroinflammation</article-title>
<source/>Horm Mol. Biol. Clin. Investig.
          <year>2018</year>
<fpage>36</fpage>
<pub-id pub-id-type="doi">10.1515/hmbci-2018-0013</pub-id>
</element-citation>
</ref>
<ref id="B115-ijms-20-05875">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crunfli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Vrechi</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Torrao</surname>
<given-names>A.S.</given-names>
</name>
</person-group>
<article-title>Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity Through Apoptosis Pathway and NO Modulation</article-title>
<source/>Neurotox. Res.
          <year>2019</year>
<volume>35</volume>
<fpage>516</fpage>
<lpage>529</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-018-9991-2</pub-id>
<pub-id pub-id-type="pmid">30607903</pub-id>
</element-citation>
</ref>
<ref id="B116-ijms-20-05875">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zha</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Endocannabinoid 2-Arachidonoylglycerol Suppresses LPS-Induced Inhibition of A-Type Potassium Channel Currents in Caudate Nucleus Neurons Through CB1 Receptor</article-title>
<source/>J. Mol. Neurosci.
          <year>2016</year>
<volume>59</volume>
<fpage>493</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-016-0761-4</pub-id>
<pub-id pub-id-type="pmid">27129498</pub-id>
</element-citation>
</ref>
<ref id="B117-ijms-20-05875">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albayram</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Alferink</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pitsch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Piyanova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Neitzert</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Poppensieker</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mauer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Legler</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging</article-title>
<source/>PNAS
          <year>2011</year>
<volume>108</volume>
<fpage>11256</fpage>
<lpage>11261</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1016442108</pub-id>
<pub-id pub-id-type="pmid">21690345</pub-id>
</element-citation>
</ref>
<ref id="B118-ijms-20-05875">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malek</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Popiolek-Barczyk</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mika</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Przewlocka</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Starowicz</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures</article-title>
<source/>Neural Plast.
          <year>2015</year>
<volume>2015</volume>
<fpage>130639</fpage>
<pub-id pub-id-type="doi">10.1155/2015/130639</pub-id>
<pub-id pub-id-type="pmid">26090232</pub-id>
</element-citation>
</ref>
<ref id="B119-ijms-20-05875">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mecha</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carrillo-Salinas</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Feliu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mestre</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guaza</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Microglia activation states and cannabinoid system: Therapeutic implications</article-title>
<source/>Pharmalcol. Ther.
          <year>2016</year>
<volume>166</volume>
<fpage>40</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2016.06.011</pub-id>
</element-citation>
</ref>
<ref id="B120-ijms-20-05875">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanaka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yagyu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sackett</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Anti-Inflammatory Effects by Pharmacological Inhibition or Knockdown of Fatty Acid Amide Hydrolase in BV2 Microglial Cells</article-title>
<source/>Cells
          <year>2019</year>
<volume>8</volume>
<elocation-id>491</elocation-id>
<pub-id pub-id-type="doi">10.3390/cells8050491</pub-id>
</element-citation>
</ref>
<ref id="B121-ijms-20-05875">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vrechi</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Crunfli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Torrao</surname>
<given-names>A.S.</given-names>
</name>
</person-group>
<article-title>Cannabinoid Receptor Type 1 Agonist ACEA Protects Neurons from Death and Attenuates Endoplasmic Reticulum Stress-Related Apoptotic Pathway Signaling</article-title>
<source/>Neurotox. Res.
          <year>2018</year>
<volume>33</volume>
<fpage>846</fpage>
<lpage>855</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-017-9839-1</pub-id>
<pub-id pub-id-type="pmid">29134561</pub-id>
</element-citation>
</ref>
<ref id="B122-ijms-20-05875">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filloux</surname>
<given-names>F.M.</given-names>
</name>
</person-group>
<article-title>Cannabinoids for pediatric epilepsy? Up in smoke or real science?</article-title>
<source/>Transl. Pediatr.
          <year>2015</year>
<volume>4</volume>
<fpage>271</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="pmid">26835389</pub-id>
</element-citation>
</ref>
<ref id="B123-ijms-20-05875">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devinsky</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Marsh</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Laux</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Flamini</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wilfong</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Filloux</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial</article-title>
<source/>Lancet Neurol.
          <year>2016</year>
<volume>15</volume>
<fpage>270</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00379-8</pub-id>
<pub-id pub-id-type="pmid">26724101</pub-id>
</element-citation>
</ref>
<ref id="B124-ijms-20-05875">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siniscalco</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bradstreet</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Cirillo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Antonucci</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages</article-title>
<source/>J. Neuroinflammation
          <year>2014</year>
<volume>11</volume>
<fpage>78</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-11-78</pub-id>
<pub-id pub-id-type="pmid">24739187</pub-id>
</element-citation>
</ref>
<ref id="B125-ijms-20-05875">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krzewska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ben-Skowronek</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Effect of Associated Autoimmune Diseases on Type 1 Diabetes Mellitus Incidence and Metabolic Control in Children and Adolescents</article-title>
<source/>Biomed. Res. Int.
          <year>2016</year>
<volume>2016</volume>
<fpage>6219730</fpage>
<pub-id pub-id-type="doi">10.1155/2016/6219730</pub-id>
<pub-id pub-id-type="pmid">27525273</pub-id>
</element-citation>
</ref>
<ref id="B126-ijms-20-05875">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domingueti</surname>
<given-names>C.P.</given-names>
</name>
<name>
<surname>Dusse</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Sousa</surname>
<given-names>L.P.</given-names>
</name>
<name>
<surname>Gomes</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<article-title>Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications</article-title>
<source/>J. Diabetes Complications
          <year>2016</year>
<volume>30</volume>
<fpage>738</fpage>
<lpage>745</lpage>
<pub-id pub-id-type="doi">10.1016/j.jdiacomp.2015.12.018</pub-id>
<pub-id pub-id-type="pmid">26781070</pub-id>
</element-citation>
</ref>
<ref id="B127-ijms-20-05875">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bermudez-Silva</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Suarez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Baixeras</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cobo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bautista</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cuesta-Munoz</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Fuentes</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Juan-Pico</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Milman</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Presence of functional cannabinoid receptors in human endocrine pancreas</article-title>
<source/>Diabetologia
          <year>2008</year>
<volume>51</volume>
<fpage>476</fpage>
<lpage>487</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-007-0890-y</pub-id>
<pub-id pub-id-type="pmid">18092149</pub-id>
</element-citation>
</ref>
<ref id="B128-ijms-20-05875">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horvath</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Magid</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mukhopadhyay</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Batkai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rajesh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Tanchian</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>R.Y.</given-names>
</name>
<name>
<surname>Goodfellow</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury</article-title>
<source/>Br. J. Pharmacol.
          <year>2012</year>
<volume>165</volume>
<fpage>2462</fpage>
<lpage>2478</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01381.x</pub-id>
<pub-id pub-id-type="pmid">21449982</pub-id>
</element-citation>
</ref>
<ref id="B129-ijms-20-05875">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoja</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Locatelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Corna</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Villa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rottoli</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nava</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Verde</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Piscitelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Di Marzo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fingerle</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy</article-title>
<source/>Nephron
          <year>2016</year>
<volume>132</volume>
<fpage>59</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1159/000442679</pub-id>
<pub-id pub-id-type="pmid">26646377</pub-id>
</element-citation>
</ref>
<ref id="B130-ijms-20-05875">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumawat</surname>
<given-names>V.S.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications</article-title>
<source/>Eur. J. Pharmacol.
          <year>2019</year>
<volume>862</volume>
<fpage>172628</fpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172628</pub-id>
<pub-id pub-id-type="pmid">31461639</pub-id>
</element-citation>
</ref>
<ref id="B131-ijms-20-05875">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vera</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lopez-Miranda</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Herradon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Abalo</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2012</year>
<volume>102</volume>
<fpage>335</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2012.05.008</pub-id>
<pub-id pub-id-type="pmid">22609797</pub-id>
</element-citation>
</ref>
<ref id="B132-ijms-20-05875">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bujalska</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy</article-title>
<source/>Pharmacology
          <year>2008</year>
<volume>82</volume>
<fpage>193</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1159/000156485</pub-id>
<pub-id pub-id-type="pmid">18810243</pub-id>
</element-citation>
</ref>
<ref id="B133-ijms-20-05875">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moriarty</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Idrees</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Finn</surname>
<given-names>D.P.</given-names>
</name>
</person-group>
<article-title>Impaired cued and spatial learning performance and altered cannabinoid CB(1) receptor functionality in the substantia nigra in a rat model of diabetic neuropathy</article-title>
<source/>Behav. Brain Res.
          <year>2016</year>
<volume>303</volume>
<fpage>61</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2016.01.027</pub-id>
<pub-id pub-id-type="pmid">26774979</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-20-05875-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Role of Cannabinoid Receptor 2 (CB2) in inflammation and the immune response. The stimulation of CB2 by its selective agonists inhibits cytokines’ production and reduces antigen presentation, modulating both inflammation and the immune response. CNR2 Q63R is a very common CB2 variant that compromises CB2 immunomodulatory properties, predisposing the individual to autoimmune disorders.</p>
</caption>
<graphic xlink:href="ijms-20-05875-g001"></graphic>
</fig>
<fig id="ijms-20-05875-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Role of Cannabinoid Receptor 1 (CB1) in Neuroinflammatory Diseases. During the inflammatory process, microglia cells overexpress CB1 and are responsible for the release of cytokines and toxic mediators. CB1 stimulation by its selective agonists has a protective role in neurons, counteracting neuroinflammation and its associated diseases.</p>
</caption>
<graphic xlink:href="ijms-20-05875-g002"></graphic>
</fig>
<table-wrap id="ijms-20-05875-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-20-05875-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>EC system main alterations in pediatric inflammatory and immune diseases.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Disease</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Main Alterations in the EC System</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Immune thrombocytopenia</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk by <italic>CNR2</italic> rs35761398 variant; reduced CB2 receptor expression in Mesenchymal Stromal Cells (MSC)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Juvenile idiopathic arthritis</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk by <italic>CNR2</italic> rs35761398 variant; presence of EC elements in synovial fluid; inflammation; RANK-L accumulation in joints</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Inflammatory bowel diseases</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk by <italic>CNR2</italic> rs35761398 variant; CB receptors hyper-expression; increased AEA levels</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Celiac Disease</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk by <italic>CNR2</italic> rs35761398 variant; increased NAPE-PDL levels; hyper-expression of CB2 receptor in duodenal mucosa and in the atrophic villous</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Obesity and NAFLD</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk by FAAH rs324420 polymorphism and <italic>CNR2</italic> rs35761398 variant</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Neuroinflammatory Diseases</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Altered expression of CB receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Type 1 diabetes mellitus</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Altered functionality of CB1 receptor in substantia nigra; CB2 receptor down-regulation</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>